We agree with FDA scientists that Keytruda is not proven to be effective for women with early stage triple negative breast cancer, but can cause serious health problems.
Read More »On Medical Treatments & Products
Dr. Diana Zuckerman’s Testimony on Moderna’s COVID Vaccine Before the FDA Advisory Committee
We need at least 1 year of blinded, randomized, controlled data. We agree that FDA should delay access to vaccines by members of the placebo group unless they are in priority populations.
Read More »NCHR’s Comments Regarding Spironolactone for Heart Failure with Preserved Ejection Fraction
What can be done to improve the quality of the data prior to FDA making a decision about whether or not to approve a new indication for spironolactone?
Read More »Testimony of Dr. Diana Zuckerman of NCHR before the FDA Advisory Committee on Pfizer COVID Vaccine
We need longer-term data on the Pfizer COVID-19 vaccine to fully understand if benefits outweigh the risks for frail patients and all races/ethnicities, and for everyone else as well. It is essential that FDA ensure the continuation of the randomized controlled trial.
Read More »Public Comments Regarding ACIP Meeting on December 1, 2020
We are concerned about the lack of data on the vaccines in patients living in long-term care facilities, or any patients over 65 years of age.
Read More »